How to deal with thrombus in ACS "Zap it" - Laser for Thrombus Suneel Talwar Dorset Heart Centre Royal Bournemouth Hospital.

Slides:



Advertisements
Similar presentations
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute.
Advertisements

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
‘SMASH IT!’ Mark Mason Interventional Cardiologist Harefield Hospital
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Advanced Angioplasty 2006 Trial Update 2 Other Trials Alun Harcombe from 1 April: Nottingham University Hospitals NHS Trust NO CONFLICT OF INTEREST TO.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
ΕΚΕ Hellenic PCI Registry ( ) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Germano Di Sciascio, MD, FACC, FESC Professor & Chairman of.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
MUSTELA : A Prospective, Randomized Trial of Thrombectomy vs. no Thrombectomy in Patients with ST-Segment Elevation Myocardial Infarction and Thrombus-Rich.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
Distal protection devices Dr Donald Baim Director, Center for Innovative Minimally Invasive Therapy Brigham & Women’s Hospital Boston, MA.
↓ 30 d mortality ↓ Distal embolization ↑ Myocardial Blush 3 ↑TIMI 3 Post De Luca et al. EHJ 2008;29:
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
AntiThrombotic Therapy in the Cath Lab: Preliminary Results from the NICE Trials Cindy L. Grines, M.D. William Beaumont Hospital Royal Oak, Michigan Cindy.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The CIAO (Coronary Interventions Antiplatelet-based Only) Study Eugenio Stabile, MD, PHD, FESC, FAHA, Wail Nammas, MD, Luigi Salemme, MD, Giovanni Sorropago,
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Total Occlusion Study of Canada (TOSCA-2) Trial
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Ben-Dor Itsik, MD Lowell Satler, MD Ron Waksman,MD Augusto Pichard, MD
Use of Laser When the Balloon Cannot Cross
Excimer Laser Atherectomy for the Treatment of Infra-inguinal Peripheral Arterial Disease Bryan P Yan MD, Thomas J Kiernan MD, Vishal Gupta MD,
Is There a Role for Aspiration in STEMI?
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Preventive Angioplasty in Myocardial Infarction Trial
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Published in the European Heart Journal
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
Elevated Admission Plasma Glucose Following ACS
Maintenance of Long-Term Clinical Benefit with
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Dye strongly persistent
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

How to deal with thrombus in ACS "Zap it" - Laser for Thrombus Suneel Talwar Dorset Heart Centre Royal Bournemouth Hospital

Conflict of Interest Consultant/Advisory Board –Spectranetics Clinical & Research Grant Support –Boston Scientific Corporation –Cordis

- Photoablation is the use of light to vaporize and remove tissue Excimer Laser

 Photochemical  Photothermal  Photomechanical Breaking molecular bonds Producing thermal energy Creating kinetic energy Mechanism of Action Three distinct mechanisms of action contribute to Excimer Laser Photoablation

 UV light pulse hits tissue for 125 billionths of a second  50 microns penetration  Billions of molecular bonds fractured per pulse billionths of a second Photochemical Mechanism: Breaking Molecular Bonds

 Absorption creates molecular vibration in tissue  Vibration of molecules heats intracellular water  Water vaporizes, rupturing cells  Steam forms expanding vapor bubble Photothermal Mechanism: Producing thermal energy

 Expansion and collapse of vapor bubble breaks down tissue and clears by-products away from tip  By-products of ablation are water, gas, and small particles (90%<10 microns = size of red blood cell) 400 millionths of a second Photomechanical Mechanism: Creating kinetic energy

The Excimer wavelength is very close to what is used in eye surgery, indicative of its shallow depth of penetration and hence safety

Affinity for Photon Absorption The Excimer wavelength is ideally suited for absorption by the acute thrombus

The Antiplatelet Effects of Laser Energy

placebo 60mj 30mj The Laser inhibits platelet aggregation acting like a localized IIB IIIa Inhibitor

Am J Cardiol 2004;93:

The data obtained from the participating centres was submitted to independent core laboratories for quantitative coronary analysis and statistical analysis.

High risk patients included 30% of the patients had Diabetes 24% had previous CABG 23% had sustained a previous MI 28% had a contraindication to thrombolysis 13% presented to the cath lab with cardiogenic shock. The target vessel for revascularisation was an old saphenous vein graft in 21% of patients.

The greater amount of thrombus the better the result with the Laser

High flow rates post laser

The CARMEL Study-Complications Death6(4%) Laser Induced Perforation0 Laser Induced dissection6(4%) Acute closure1(0.6%) Laser induced no-flow1(0.6%) Stent induced no-flow1(0.6%) Groin bleeding complications3 (2%)

Study Summary Extended FAMILI Flow in Acute Myocardial Infarction Patients after Laser Intervention - Extended Pilot Study

Extended FAMILI Objective: To benchmark microvascular coronary blood flow in AMI patients after percutaneous intervention that includes excimer laser coronary atherectomy Study Design: Prospective non-randomized study in up to 20 sites, and up to 80 patients. Principal Investigators: Jeffrey Moses, MD Antonio Columbo, MD

EXTENDED FAMILI RESULTS Laser Success: Defined as TIMI 2-3 with > 20% reduction in %DS post laser. Procedure Success: Defined as TIMI 3 flow and < 50% DS on final angiogram without in-hospital MACE. - Laser Success: 94% - Procedure Success: 96% - 30 Day-MACE: 3% Low MACE correlated with the high Blush Scores

EXTENDED FAMILI

Svilaas T et al. N Engl J Med 2008;358: Thrombus Aspiration during Primary PCI: TAPAS study

Extended FAMILI: Conclusions –Laser appears safe for thrombus ablation in Acute MI: 30 Day MACE 3% –High Procedural Success Rate of 91% –Extended FAMILI appears equivalent in TIMI flow rates compared to other thrombectomy studies. –Blush scores post-procedure appear to be significantly better than the other thrombectomy studies..

TAAMI: Thrombus Ablation in Acute Myocardial Infarction Randomised controlled study comparing a Laser-Stent strategy to a Balloon-Stent strategy N= sites in Poland

TAAMI: Thrombus Ablation in Acute Myocardial Infarction Primary Endpoint -Complete ST resolution and MBG 3 immediately post procedure Secondary Endpoint -MACE 30 days -MBG -TIMI Flow rates post Laser -TIMI frame count -ST reolution at 60 minutes post procedure

Our Approach in AMI Turn on the Laser prior to arrival of patient in the Lab to avoid delays Laser Catheter: For most total occlusions start with a 0.9/1.4 catheter (both are 6F compatible) The laser will work over any wire The vapor bubble works best in a saline medium (blood and contrast must be flushed prior to lasing) Activate the laser a few mm proximal to the start of the lesion – to maximize the effect of the advancing vapor bubble –and to avoid cavitation into the plaque Use higher energies and rates from the start (60/40) – to create a larger vapor bubble – and lead to better inhibition of platelet aggregation In order to get the effect of the advancing vapor bubble, the laser catheter must be advanced very slowly (rate of <1mm per second)

Conclusion The use of the excimer laser is feasible and safe in the setting of an AMI Laser treatment has been shown to result in significant thrombus removal, suggesting direct laser energy absorption and thrombus vaporisation The potential clinical benefits of the stunned platelet phenomenon await clinical confirmation A prospective randomised multicentre comparing this to convention angioplasty and stenting as well as thrombectomy is necessary to confirm the observations made so far